AndroGel (Testosterone Topical) Transfer to Women and Children: The Biology of Why It Happens

What Secondary Testosterone Exposure Actually Means

Secondary exposure means a person who did not apply testosterone gel absorbs a pharmacologically active amount of testosterone because they touched skin or clothing bearing residual gel. In the Feldman (2005) pharmacokinetic study, untreated female partners showed serum testosterone levels two to three times above their baseline after 15 minutes of skin contact with a male torso treated with 5 g of testosterone 1% gel, without a barrier in place [1].

Residue Is Not Invisible

Most users assume the gel disappears once it dries. It does not disappear in a pharmacological sense. Testosterone remains on the skin surface in a depot layer for roughly 2 hours post-application [1]. Anyone pressing bare skin against that area during that window absorbs hormone through their own stratum corneum.

Why This Matters Clinically

Testosterone is a Class III controlled substance with no safe dose in prepubertal children or women who are pregnant or may become pregnant [2]. Even transient elevation can initiate androgenic gene expression cascades. The Endocrine Society's 2018 guideline states directly: "Clinicians should advise patients to avoid skin-to-skin contact with application sites in women and children" [3].

The Skin Barrier: How Testosterone Crosses It

Testosterone is a lipophilic steroid with a molecular weight of 288 g/mol and a log P (octanol/water partition coefficient) of approximately 3.3. Those properties make it an excellent candidate for percutaneous absorption, which is precisely why gel formulations work as a delivery route in the first place [4].

Partition from Gel into Stratum Corneum

When testosterone 1% gel is applied, ethanol and other co-solvents in the vehicle drive the hormone into the outer dead-cell layer of skin (stratum corneum). As the ethanol evaporates over the first 30 minutes, a supersaturated testosterone film remains. The skin of a contact partner pressed against that film encounters a high-concentration gradient pointing inward. Fick's first law of diffusion means flux scales directly with that gradient [4].

Passage Through the Viable Epidermis and Dermis

Below the stratum corneum, viable keratinocytes and dermal fibroblasts express 5-alpha-reductase, which converts a fraction of absorbed testosterone into dihydrotestosterone (DHT). Both testosterone and DHT bind androgen receptors in target tissues [5]. The Endocrine Society notes that the ratio of DHT to testosterone produced in skin is higher than in most other tissues, which may amplify virilizing effects in recipients even when total transferred testosterone amounts are small [3].

Entry into Systemic Circulation

Testosterone that passes through the dermis enters capillary blood flow. In men receiving 5 g of AndroGel 1%, steady-state serum testosterone reaches approximately 550 ng/dL, a normal male range [6]. In a prepubertal child whose endogenous testosterone may be <10 ng/dL, even a transfer-driven rise to 50 ng/dL represents a five-fold supra-physiological signal against a very low baseline.

Why Some Transfers Cause Harm and Others Do Not

Transfer risk is not uniform. Four variables determine whether a contact event produces measurable androgenic effects.

Amount of Residual Testosterone on the Applicator's Skin

A man applying the maximum labeled dose of AndroGel 1.62% (81 mg testosterone, corresponding to 5 g gel) deposits more surface residue than a man on the minimum dose (20.25 mg, 1.25 g gel). Cmax in treated men scales linearly with dose [6]. The surface depot available to transfer scales the same way.

Duration and Area of Contact

The FDA-reviewed virilization cases in children involved prolonged daily contact, typically fathers sitting with children on their laps or sharing beds without covering the application site [2]. Brief incidental contact carries a lower transfer burden than sustained bare-skin embrace.

The Recipient's Absorption Efficiency

Children have thinner stratum corneum, higher skin surface area relative to body mass, and higher transepidermal water loss than adults. All three factors increase percutaneous absorption per unit dose relative to adult women [7]. This is why pediatric cases in FAERS have shown more dramatic and faster-onset virilization than cases in adult female partners [2].

Time Elapsed Since Application

The phase I pharmacokinetic data for AndroGel 1% shows that washing the application site with soap and water 6 hours after application reduces residual surface testosterone to near zero [6]. The transferable window is therefore concentrated in the first 2 hours, tapering substantially between hours 2 and 6.

Documented Clinical Effects in Women

Adult women exposed to testosterone gel via partner contact show a recognizable cluster of androgenic signs. A 2009 FDA Drug Safety Communication summarizing postmarketing reports listed deepened voice, clitoral enlargement, increased libido, acne, and menstrual irregularities as the predominant findings in female contacts [2].

Hormonal Mechanism in Women

Women normally maintain serum testosterone between 15 and 70 ng/dL. Testosterone regulates libido, erythropoiesis, and bone mineral density in women, but supra-physiological levels suppress LH and FSH via hypothalamic-pituitary negative feedback, disrupt ovarian cyclicity, and drive androgenic receptor activity in sebaceous glands, hair follicles, and the clitoris [8].

Pregnancy Risk

Testosterone is teratogenic. FDA labeling for AndroGel assigns Pregnancy Category X, meaning studies show fetal harm and risk clearly outweighs any benefit [6]. Fetal virilization from maternal androgen exposure can produce ambiguous genitalia in female fetuses. Pregnant women in households where a partner uses topical testosterone must never contact application sites [2].

Breast-Feeding Concerns

Testosterone is present in human milk. Although transfer kinetics in lactating women exposed via skin contact have not been formally studied, the precautionary principle applied by the FDA label recommends that breastfeeding women avoid application-site contact entirely [6].

Documented Clinical Effects in Children

The pediatric cases that prompted the 2009 black-box warning were stark. Children exposed to household testosterone gel showed [2]:

• Pubic and axillary hair growth before age 2 in several cases
• Clitoral or penile enlargement
• Bone age advancement on radiograph
• Elevated serum testosterone confirmed by lab draw

Why Children Are the Highest-Risk Group

Prepubertal children have essentially zero endogenous androgen production from the gonads. The hypothalamic-pituitary-gonadal axis is quiescent. Any exogenous testosterone therefore acts unopposed, and even small amounts can trigger gonadotropin-independent precocious puberty [9]. A single transferable dose from one application of AndroGel to a child's skin may be enough to advance bone age by months, which permanently reduces adult height potential if not identified quickly.

Bone Age and Growth Plate Closure

Androgens accelerate epiphyseal growth plate maturation. In normal male puberty this process takes years. In a child with chronic low-level testosterone exposure from household transfer, growth plate advancement can outpace linear height gain, producing a child who is initially tall but ends up shorter than their genetic potential [9]. Endocrinologists typically obtain a left-hand and wrist X-ray (Greulich-Pyle method) when evaluating potential androgen exposure in children.

Case-Level Evidence

The FDA's 2009 review cited 20 or more cases of pediatric virilization reported to FAERS, predominantly in children under age 5 [2]. A case series published in Pediatrics (Kunz et al., 2004) described three boys with penile enlargement and pubic hair who all had fathers using testosterone gel; serum testosterone in the children ranged from 66 to 460 ng/dL, compared with an age-appropriate reference of <10 ng/dL [10].

The Pharmacokinetics of Transfer: What the Numbers Show

The most informative transfer study to date assessed female partners of men on 5 g/day testosterone 1% gel under controlled contact conditions [1]. Key findings:

• Without barrier (shirt), female partner AUC for testosterone was 2.4-fold above baseline after a 15-minute contact period
• With a shirt covering the application site, no statistically significant rise in female serum testosterone was detected
• Washing the male application site with soap and water before contact reduced female serum testosterone AUC to near-baseline levels

These three data points form the practical basis for all current prevention recommendations. The same trial found that application to the abdomen (as permitted by the 1.62% labeling) did not meaningfully increase or decrease transfer risk compared to shoulder or upper-arm application when contact occurred at the same interval post-application [1].

Serum Testosterone Timecourse in Exposed Recipients

After a single transfer event, serum testosterone in a female contact peaks within 2 to 4 hours and returns toward baseline within 24 hours, given the short half-life of exogenous testosterone (approximately 70 minutes for unmodified testosterone in circulation) [4]. Repeated daily contact, however, produces cumulative steady-state elevation because daily re-exposure occurs before the previous day's transferred dose fully clears.

What "Measurable" Means vs. What "Harmful" Means

Statisticians and regulators draw different thresholds. Measurable transfer (detectable serum testosterone above pre-contact baseline) occurs with essentially any unprotected contact during the 2-hour post-application window [1]. Harmful transfer (clinical virilization, hormonal disruption, or fetal risk) requires repeated or prolonged exposure [2]. That distinction supports risk-reduction rather than household segregation as the primary management strategy.

The FDA's Regulatory Response

The FDA issued a Drug Safety Communication in May 2009 requiring a black-box warning on all topical testosterone products, including AndroGel 1%, Testim, and subsequently AndroGel 1.62% [2]. The warning specifies:

• Children and women should avoid contact with application sites
• Patients should wash hands immediately after application
• Patients should cover the application site with clothing after the gel dries
• The application site should be washed before anticipated skin-to-skin contact

Prescribers are directed to counsel male patients on these points at every prescription. The label also requires a Medication Guide be dispensed with each prescription [6].

REMS Considerations

At the time of the 2009 communication, the FDA considered but did not require a Risk Evaluation and Mitigation Strategy (REMS) for topical testosterone products, concluding that the black-box warning and mandatory Medication Guide provided sufficient risk communication [2]. The agency has continued to monitor FAERS for new cases.

FAERS Signal Over Time

Postmarketing surveillance through FAERS continues to log pediatric virilization and female androgenization cases associated with testosterone gel products. The signal has not disappeared since the 2009 label change, which suggests that patient counseling at the point of prescribing remains inconsistent [2].

Endocrine Society and Clinical Guideline Recommendations

The 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy in men (Bhasin et al.) gives a Grade A recommendation that prescribers "inform patients about the risk of skin transfer of testosterone to women and children and advise measures to prevent such transfer" [3]. This is the highest-evidence recommendation category the guideline uses.

Monitoring for Exposed Individuals

The guideline does not specify a monitoring serum testosterone threshold for exposed women but recommends clinical evaluation for virilization symptoms at each visit [3]. For children with suspected exposure, the American Academy of Pediatrics recommends measurement of serum total testosterone, LH, FSH, and a bone age radiograph [9].

Counseling Frequency

A 2021 survey study found that fewer than 40% of testosterone gel users recalled receiving specific transfer-risk counseling at the time of their most recent prescription fill [11]. This gap between guideline recommendation and practice is likely a primary driver of continued FAERS reports. Telehealth prescribers carrying testosterone panels face the same responsibility as in-office providers to document transfer counseling.

Prevention: What Reduces Transfer Risk

Three interventions, used in combination, reduce transfer risk to near zero in pharmacokinetic studies.

Handwashing

Washing hands with soap and water immediately after applying testosterone gel removes residual hormone from the palms and fingers. This step takes 20 seconds but eliminates one of the primary indirect transfer routes (hand-to-skin contact with a partner) [6].

Clothing Barrier

Covering the application site with a cotton T-shirt after the gel dries (roughly 5 minutes after application) reduces skin-to-skin transfer by approximately 95% in the Feldman study [1]. The shirt acts as a physical barrier that prevents direct skin apposition.

Site Washing Before Contact

For situations where intimate skin contact will occur within 2 hours of application, washing the application site with soap and water before contact returns residual surface testosterone to near-zero [1]. Couples who share a bed or engage in physical intimacy should build this step into their routine.

Timing of Application

Some prescribers advise patients to apply AndroGel at bedtime rather than in the morning, given that absorption is essentially complete within 2 hours and the household contact risk during sleep can be mitigated by wearing a T-shirt [12]. Morning application is listed in the label as the standard approach, so any timing change should be made in consultation with the prescribing clinician [6].

Biological Sex Differences That Modify Transfer Outcome

The androgenic impact of transferred testosterone differs between adult women and prepubertal children not just because of dose differences but because of receptor sensitivity, co-factor expression, and end-organ responsiveness.

Androgen Receptor Density

Prepubertal children have high androgen receptor density in genital skin, pubic tissue, and axillary tissue because these tissues are primed to respond to the pubertal testosterone surge that has not yet arrived. That receptor density means a small transferred dose can produce a large downstream effect [9].

Sex Hormone Binding Globulin

Women generally carry higher serum levels of sex hormone binding globulin (SHBG) than men, which binds free testosterone and limits bioavailability [8]. Despite this buffer, free testosterone still rises measurably in female contacts after transfer events [1]. Children have lower SHBG than adult women, which may partly explain their greater clinical sensitivity to transferred testosterone [9].

Aromatase Activity

Women convert a significant fraction of testosterone to estradiol via aromatase in adipose and breast tissue. This conversion pathway is less active in prepubertal children, meaning transferred testosterone in children remains as testosterone or is reduced to DHT rather than being shunted to estrogen, sustaining a purely androgenic signal [5].

What Patients and Families Need to Know

The biology is complex. The prevention message is not. Three behaviors, applied consistently, protect household contacts:

1. Wash hands after every application.
2. Cover the application site with a shirt before any skin contact.
3. Wash the application site with soap and water before intimate or child contact if that contact will occur within 2 hours of application.

A 2019 study in the Journal of Clinical Endocrinology and Metabolism found that adherence to all three measures was associated with no detectable change in serum testosterone in female partners over a 4-week observation period [12]. Zero transfer is achievable. It requires consistent behavior, not cessation of therapy.